about us

About BioCardia

We are developing cellular and cell-derived therapeutics for the treatment of unmet cardiovascular and pulmonary diseases.

Our Mission:
To improve the lives of patients with cardiovascular and pulmonary diseases through the development of meaningful therapeutics.

Our Pipeline: 
Our four clinical stage marrow derived cell therapy programs include autologous (using a patient's own cells) and allogeneic (using cells manufactured from patient donors) approaches.   None of our therapeutic candidates require post procedure immunosuppression in their clinical investigations and all are delivered to the target tissue in a minimally invasive fashion.

Our lead autologous FDA designated "Breakthrough" investigational  CardiAMP® mononuclear cell therapy is intended for the treatment of ischemic heart failure (BCDA-01)    This cell therapy is manufactured at the patient’s bedside using the proprietary CardiAMP cell processing system just before treatment and delivered via a catheter based minimally invasive approach.  This autologous cell therapy is being advanced for a second cardiac clinical indication of  chronic myocardial ischemia with refractory angina (BCDA-02).   Its mechanism of action, demonstrated in preclinical research, is to promote enhanced capillary density and reduce fibrosis, which are believed to underlie the positive results in clinical trials to date. 

Our investigational culture expanded allogeneic mesenchymal stem cell (MSC) platform is  an “off the shelf” cell therapy manufactured by BioCardia.  These cells are being advanced clinically as CardiALLO™ for the treatment of heart failure (BCDA-03) and as PulmALLO™ for the treatment of acute respiratory distress syndrome (BCDA-04). Its mechanism of action includes immunomodulatory benefits in inflammatory disease substrates.

Our therapeutic development strategies incorporate personalized and precision medicine to enable the patients most likely to benefit from these therapies to receive them.  Therapies are also delivered in a local targeted fashion to the tissue most in need to maximize their therapeutic window for patient benefit.  For our three cardiovascular indications, local targeted delivery is performed with our proprietary Helix™ transendocardial biotherapeutic delivery system (Helix system).  This is a therapeutic-enabling platform for minimally invasive targeted delivery of biologic agents to the heart.  The Helix system empowers a seamless transition from bench to commercialization for partners.  Navigation within the heart using the Helix system is enabled by our proprietary Morph® DNA steerable introducer products.